First Trust Advisors LP Has $14.68 Million Position in Nu Skin Enterprises, Inc. (NUS)
First Trust Advisors LP trimmed its stake in shares of Nu Skin Enterprises, Inc. (NYSE:NUS) by 25.6% in the 3rd quarter, HoldingsChannel reports. The firm owned 178,092 shares of the company’s stock after selling 61,385 shares during the period. First Trust Advisors LP’s holdings in Nu Skin Enterprises were worth $14,678,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NUS. OppenheimerFunds Inc. boosted its position in shares of Nu Skin Enterprises by 80.5% during the 2nd quarter. OppenheimerFunds Inc. now owns 267,285 shares of the company’s stock worth $20,899,000 after acquiring an additional 119,244 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of Nu Skin Enterprises by 16.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 21,674 shares of the company’s stock worth $1,695,000 after acquiring an additional 3,038 shares in the last quarter. ING Groep NV boosted its position in shares of Nu Skin Enterprises by 12.9% during the 2nd quarter. ING Groep NV now owns 8,518 shares of the company’s stock worth $666,000 after acquiring an additional 976 shares in the last quarter. RBO & Co. LLC acquired a new position in shares of Nu Skin Enterprises during the 2nd quarter worth about $227,000. Finally, Barings LLC boosted its position in shares of Nu Skin Enterprises by 342.8% during the 2nd quarter. Barings LLC now owns 24,930 shares of the company’s stock worth $1,949,000 after acquiring an additional 19,300 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have recently issued reports on NUS shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $98.00 price objective on shares of Nu Skin Enterprises in a research report on Tuesday, September 4th. Zacks Investment Research raised Nu Skin Enterprises from a “sell” rating to a “hold” rating in a research report on Monday, October 15th. DA Davidson started coverage on Nu Skin Enterprises in a research report on Tuesday, October 9th. They set a “buy” rating and a $92.00 price objective for the company. Stifel Nicolaus raised Nu Skin Enterprises from a “sell” rating to a “hold” rating and upped their price objective for the stock from $57.00 to $70.00 in a research report on Thursday, August 2nd. They noted that the move was a valuation call. Finally, Citigroup set a $88.00 price objective on Nu Skin Enterprises and gave the stock a “buy” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company’s stock. Nu Skin Enterprises presently has a consensus rating of “Buy” and a consensus target price of $86.29.
Nu Skin Enterprises (NYSE:NUS) last announced its earnings results on Wednesday, November 7th. The company reported $0.94 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.02). The firm had revenue of $675.31 million during the quarter, compared to analyst estimates of $664.99 million. Nu Skin Enterprises had a net margin of 5.93% and a return on equity of 28.06%. The firm’s revenue for the quarter was up 19.8% compared to the same quarter last year. During the same period last year, the company earned $0.76 earnings per share. As a group, research analysts forecast that Nu Skin Enterprises, Inc. will post 3.52 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 12th. Investors of record on Friday, November 30th will be given a $0.365 dividend. The ex-dividend date of this dividend is Thursday, November 29th. This represents a $1.46 dividend on an annualized basis and a dividend yield of 2.25%. Nu Skin Enterprises’s dividend payout ratio (DPR) is presently 45.20%.
In related news, General Counsel D Matthew Dorny sold 2,500 shares of the company’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $79.90, for a total value of $199,750.00. Following the completion of the sale, the general counsel now directly owns 33,871 shares of the company’s stock, valued at approximately $2,706,292.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 5.20% of the stock is owned by corporate insiders.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems and targeted treatment products, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic, personal care, and hair care products.
Further Reading: What is a Call Option?
Want to see what other hedge funds are holding NUS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nu Skin Enterprises, Inc. (NYSE:NUS).
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.